Eurofins Scientific (EUFI.PA) (Paris:ERF), a global scientific leader in bioanalytical testing, acquired Beacon Discovery, a San Diego, CA-based drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research.
The transaction, whose amount was not disclosed, is expected to close in the coming weeks upon fulfilment of customary closing conditions.
The addition of Beacon Discovery augments Eurofins Discovery’s capabilities and innovative methods to support and accelerate drug discovery research and development and capitalize on the growing R&D outsourcing market. Beacon Discovery joined Eurofins Discovery, a CRO with a broad portfolio of validated in vitro pharmacology, ADMET, and chemistry services for integrated drug discovery solutions.
Founded in 2016 and led by Dr. Sunny Al-Shamma, CEO, Beacon Discovery is a world leader in GPCR-focused drug discovery. Its internal pipeline focuses on GPCRs for which the native ligand remains unknown. These orphan GPCRs provide opportunities to develop novel drugs addressing significant unmet medical need. In addition, Beacon collaborates with biopharma partners to leverage internally enabled GPCR targets and small molecule modulators as well as its wealth of GPCR discovery skills and tools.
Led by Dr. Gilles Martin, CEO, Eurofins is a global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. It is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations.
The group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
It has over 50,000 staff across a decentralised and entrepreneurial network of more than 800 laboratories in over 50 countries.